Role of ezetimibe in the management of patients with atherosclerosis.
Lowering low-density lipoprotein cholesterol is central to the management of patients at risk of atherosclerosis. Traditional treatment has focused on modifying the endogenous lipid pathway using statins. Ezetimibe, a selective inhibitor of cholesterol absorption, has proved to be highly effective in lowering low-density lipoprotein cholesterol, and its use has soared, especially in the United States. Unfortunately, there is currently no evidence proving that treatment with ezetimibe is linked to a reduction in cardiovascular events; therefore, its choice as a drug to lower cholesterol is currently controversial.